FDA PCAC Is Meeting to Review 7 Peptides July 2026: What It Means

The peptide space has been moving fast. In February 2026, the HHS Secretary announced plans to make peptides more accessible through lawful compounding channels since being restricted in 2023. In April, the FDA formally removed 12 peptides from Category 2 and announced a public review process.

Here’s a quick timeline of the events:

That review happens July 23-24, 2026, and it's coming up fast.

Here is what the meeting actually is, what it covers, and what it does and does not mean for healthcare organizations.

What is the Pharmacy Compounding Advisory Committee (PCAC)?

The Pharmacy Compounding Advisory Committee functions as a federal advisory committee that provides independent expert advice, technical, and scientific recommendations to the FDA Commissioner regarding drug compounding issues under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Why Is the PCAC Meeting Happening in July 2026?

The PCAC meeting will be held to evaluate and give recommendations on seven peptides being considered for reclassification to be added to the 503A Bulk Substances List.

The July 23-24 meeting will be held at the FDA's White Oak Campus in Silver Spring, Maryland, and is open to the public. Nominators of each substance will present supporting data. Independent experts will evaluate the evidence. The FDA will then consider those recommendations before deciding whether to initiate formal rulemaking.

This is the first formal, public, evidence-based scientific review most of hese peptides have ever received. In  2023 the FDA placed 19 peptides or peptide related bulk drug substances into Category 2 based on their concerns regarding patient safety risks and lack of sufficient  information or human exposure data.Their decision to bypass the standard review process drew significant criticism from wellness experts, compounding pharmacies and legal analysts 

Which Peptides Are Being Reviewed?

Seven peptides are on the agenda across two days. (FDA.gov, Docket No. FDA-2025-N-6895)

July 23:

• BPC-157

• KPV

• TB-500

• MOTs-C

July 24:

• Emideltide (DSIP)

• Semax

• Epitalon

For organizations in longevity, hormone health, and performance medicine, several of these are directly relevant to programs your patients are already asking about.

A second PCAC meeting is scheduled before February 2027 to review five additional peptides: 

• GHK-Cu

• Cathelicidin LL-37

• Dihexa Acetate

• PEG-MGF

• Melanotan II.

What Does a PCAC Recommendation Actually Mean?

This is the most important thing to understand before July 23.

PCAC recommendations are non-binding. The committee evaluates the evidence and makes a recommendation to the FDA. The FDA then decides whether to act on it. A positive recommendation does not restore compounding access. It does not make a peptide approved to compound. It is one step in a longer process.

Even if PCAC recommends adding all seven peptides to the 503A Bulks List, compounding pharmacies cannot legally prepare them until the FDA completes formal rulemaking. That process includes publishing a Notice of Proposed Rulemaking, opening a public comment period, and issuing a final rule. Under standard timelines, that takes 12 to 24 months.

And even after formal rulemaking is complete and a peptide reaches Category 1 status, it is still not FDA-approved. Category 1 means the FDA does not intend to take enforcement action against 503A pharmacies compounding that substance for individual patients, provided all other conditions are met. It is an interim enforcement position, not a drug approval.

What Comes Next After the PCAC Meeting?

The July 23-24 meeting is a milestone, not a finish line. Here is what the process looks like after PCAC wraps:

• PCAC issues recommendations for each peptide (non-binding)

• FDA reviews recommendations and decides whether to accept, modify or reject PCAC’s recommendations entirely and then, if appropriate, initiate rulemaking

• FDA publishes a Notice of Proposed Rulemaking

• Public comment period opens

• FDA issues a final rule adding substances to the 503A Bulks List

• Compounding would be legally permitted under Category 1.

Most analysts estimate this process will take until mid-to-late 2026 at the earliest, with 2027 being the more realistic target for final determinations.

What Should Your Organization Do Now?

The July meeting signals the direction. But the time between now and formal rulemaking is exactly when preparation pays off.

• Audit your pharmacy partnerships. Confirm third-party testing, FDA-registered prescription grade API sourcing, 503A pharmacy state licensing coverage, and USP 797 compliance now, before patient volume accelerates.

• Build your clinical protocols. Documented clinical rationale, patient-specific prescriptions, and informed consent processes take time to build correctly. Start now.

• Map your state compliance gaps. Federal Category 1 status does not automatically satisfy state requirements. State-by-state enforcement of peptides may differ. Know where your gaps are before you scale.

• Monitor the docket. Public comments and formal updates will appear at (FDA-2025-N-6895). Set up monitoring now.

Be Ready for Any Peptide Reclassification with OpenLoop

Peptide compounding regulations are still evolving, and the potential reclassification of seven peptides could shift access quickly. Thankfully, OpenLoop provides white-label infrastructure support across key operational and regulatory components:

• Access to compounded medications through licensed 503A pharmacy partners (where permitted by law)

• Medically reviewed, repeatable protocols

• Licensed clinician network with credentialing and oversight across all 50 states

• Compliance-aligned infrastructure designed to adapt as federal and state regulations evolve

• Patient support services available 24/7/365

You focus on your brand. OpenLoop handles the rest. Contact our team to get started. 

This content is for general informational purposes only and does not constitute legal or medical advice. Regulatory classifications are subject to change. Consult qualified legal counsel and clinical advisors for guidance specific to your organization.

*This content is intended for general informational purposes only and should not be construed as legal advice. For guidance on your specific situation, please consult a licensed attorney.